

# VFC Resolution Update: Pneumococcal Vaccines

Jeanne M. Santoli ([jsantoli@cdc.gov](mailto:jsantoli@cdc.gov))  
Immunization Services Division  
National Center for Immunization and  
Respiratory Diseases  
February 20, 2013



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
CENTERS FOR DISEASE CONTROL AND PREVENTION



SAFER · HEALTHIER · PEOPLE

# Overview

**NOTE: The VFC resolution for pneumococcal vaccines contains two components—the PCV component and the PPV23 component.**

**This update pertains only to the PCV component of the resolution—there are no proposed changes to the PPV23 component.**

# Purpose and Eligible Groups

## ■ Purpose

The purpose of this resolution is to update recommendations regarding the use of this vaccine in PCV13-naïve children aged 6-18 years.

## Eligible groups—current wording unchanged

- All infants and children at least six weeks through 59 months of age and children 60 through 71 months with certain underlying medical conditions listed in the table below.
- Children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease because of sickle cell disease, HIV-infection, or other immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.

Note: The table on the next slide is labeled as Table 1 in the VFC resolution.

**Table 2** Underlying medical conditions that are indications for pneumococcal vaccination among children

<b>Immunocompetent persons</b>	Chronic heart disease*
	Chronic lung disease**
	Diabetes mellitus
	Cerebrospinal fluid leaks
	Cochlear implant
<b>Functional or anatomic asplenia</b>	Sickle cell disease (SCD) and other hemoglobinopathies Congenital or acquired asplenia, or splenic dysfunction
<b>Immunocompromised persons</b>	HIV infection
	Chronic renal failure and nephrotic syndrome
	Diseases associated with immunosuppressive chemotherapy, or radiation therapy including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation
	Congenital immunodeficiency***
* Particularly cyanotic congenital heart disease and cardiac failure	
** Including asthma if treated with high-dose oral corticosteroid therapy	
*** Includes B- (humoral) or T-lymphocyte deficiency; complement deficiencies, particularly C1, C2, C3, and C4 deficiency; and phagocytic disorders (excluding chronic granulomatous disease)	

# Recommended Schedule and Dosage Intervals Part 1

Age	Vaccination history: total number of PCV7 and/or PCV13 doses received previously	Recommended PCV13 Regimen <sup>1</sup>
<b>2–6 mo</b>	0 doses	3 doses, 8 weeks apart; fourth dose at age 12–15 mos
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12–15 mos
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12–15 mos
<b>7–11mo</b>	0 doses	2 doses, 8 weeks apart; third dose at 12–15 mos
	1 or 2 doses before age 7 mo	1 dose at age 7–11 mos, with a second dose at 12–15 mos ( $\geq 8$ weeks later)
<b>12–23 mo</b>	0 doses	2 doses, $\geq 8$ weeks apart
	1 dose before age 12 mo	2 doses, $\geq 8$ weeks apart
	1 dose at $\geq 12$ mo	1 dose, $\geq 8$ weeks after the most recent dose <sup>2</sup>
	2 or 3 doses before age 12 mo	1 dose, $\geq 8$ weeks after the most recent dose <sup>2</sup>
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, $\geq 8$ weeks after the most recent dose*

# Recommended Schedule and Dosage Intervals Part 2

<b>24- 71 mo</b>		
Children with underlying medical conditions as defined in Table 1 <sup>3</sup>	Any incomplete schedule of $\leq 2$ doses	2 doses, one $\geq 8$ weeks after the most recent dose and another dose $\geq 8$ weeks later
	Any incomplete schedule of 3 doses	1 dose, $\geq 8$ weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, $\geq 8$ weeks after the most recent dose*
<b>6-18 years</b>		
Children who are at increased risk for invasive pneumococcal disease as defined in footnote 4.	Not previously vaccinated with PCV 13	1 dose

# Recommended Schedule and Dosage Intervals

## Table Footnotes

### Footnotes:

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 2) No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) For children with underlying medical conditions (see Table 1), PCV13 is indicated through 71 months of age.
- 4) Includes children with anatomic or functional asplenia, including sickle cell disease, HIV-infection or other immunocompromising condition, cochlear implant, or cerebrospinal fluid leak.

\* A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

# PCV Component of the VFC Resolution

Recommended dosage—current wording unchanged

- Refer to product package inserts.

Contraindications and Precautions—updated

- Contraindications and precautions can be found at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5911a1.htm>



# Statement Regarding Update Based on Published Documents

**[If an ACIP recommendation regarding pneumococcal vaccination is published within 12 months following this resolution, the relevant language above (except in the eligible groups sections) will be replaced with the language in the recommendation and incorporated by reference to the publication URL.]**